Clinical Nuclear Medicine 2020
DOI: 10.1007/978-3-030-39457-8_36
|View full text |Cite
|
Sign up to set email alerts
|

Radioembolization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 136 publications
0
1
0
Order By: Relevance
“…RAI treatment, PRRT and PSMA-TRT have been indicated in the treatment of hyperthyroidism and well-differentiated thyroid cancer, metastatic neuroendocrine tumors (NETs) and metastatic castration-resistant prostate cancer, respectively [2,3,6,7]. Further, transarterial radionuclide embolization (TARE) is a commonly used selective radionuclide therapy targeting unresectable primary and metastatic liver cancer [8]. RAI therapy, PSMA-TRT, PRRT and TARE are the most commonly performed radionuclide treatments that are specific to nuclear medicine expertise.…”
Section: Introductionmentioning
confidence: 99%
“…RAI treatment, PRRT and PSMA-TRT have been indicated in the treatment of hyperthyroidism and well-differentiated thyroid cancer, metastatic neuroendocrine tumors (NETs) and metastatic castration-resistant prostate cancer, respectively [2,3,6,7]. Further, transarterial radionuclide embolization (TARE) is a commonly used selective radionuclide therapy targeting unresectable primary and metastatic liver cancer [8]. RAI therapy, PSMA-TRT, PRRT and TARE are the most commonly performed radionuclide treatments that are specific to nuclear medicine expertise.…”
Section: Introductionmentioning
confidence: 99%